Since its inception about three decades ago, the fundamentals of software and hardware design for deep brain stimulation (DBS) have largely remained stagnant. However, improved understanding of disease progression pertaining to movement disorders combined with patient and clinician demands has led to the development of more advanced DBS technology. This will open growth avenues for deep brain stimulation and its allied realms, according to a research report by Transparency Market Research.
While new electrode design for deep brain stimulation devices has enabled multi-target stimulation sans side-effects, new user-friendly software enables computational modelling and individualized directed programming.
Q. What is the usability of DBS devices for Parkinson’s disease?
A. The use of deep brain stimulation for Parkinson’s disease involves treating several disabling neurological symptoms such as tremor, slowed movement, rigidity, stiffness, and walking problems. While drug therapy is most commonly used for the treatment of Parkinson’s disease in initial stages, surgical intervention using DBS devices are used to control the symptoms of the disease in advanced stages.
DBS devices are effective, clinically proven and have received legal approvals for the advanced treatment of mild to severe form of Parkinson’s disease. The endorsements for the usability of these devices will benefit the growth of the deep brain stimulation devices market.
Q. How have technological advances benefitted the growth of the DBS devices market?
A. Tremendously. In a recent industry development, GlaxoSmithKline and Verily have joined hands to establish Galvani Bioelectronics – a joint venture for the development miniature implantable devices to modify nerve signals and also to collect information about the body’s neural networks. These miniature devices are designed to communicate with a hand-held receiver and leverage analytics and to treat patients more precisely.
This technology has been announced as bioelectronics medicine that works on the target area, unlike drugs that affect the entire body.
Q. What are the major factors propelling the growth of deep brain stimulation devices market?
A. The global deep brain stimulation devices market is driven by several factors. A rising geriatric population globally, an increasing incidence of Parkinson’s disease, and rising awareness about neurological movement disorders is fuelling the growth of this market. Moreover, favorable reimbursement policies are also contributing to the growing acceptance of these devices across the world.
Q. What are the factors holding back the growth of the deep brain stimulation devices market?
A. The risks associated with deep brain stimulation surgeries are the foremost factor holding back the market’s growth. Furthermore, the implementation of certain governmental policies such as the Affordable Care Act in the U.S. will hinder the growth of this market to some extent.
The high-cost factor of deep brain stimulation surgical procedure is also restraining the market’s growth. However, the growing burden of Parkinson’s disease on healthcare systems of developed countries has necessitated original equipment manufacturers (OEMs) to develop cost-effective devices for the treatment of Parkinson’s disease.